Effectiveness of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligosynovitis Resistant to Prior TNF-<i>α</i> Inhibitors

<div>A representative result of US of the wrist of case 3 demonstrated PD-positive synovitis before treatment with CZP. US showed disappearance of PD-positive inflammatory synovitis after treatment with CZP.</div>

Case Reports in Rheumatology

fig1

Figure 1

Figure 1: Effectiveness of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligosynovitis Resistant to Prior TNF-<i>α</i> Inhibitors 

Figure 1 | Effectiveness of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligosynovitis Resistant to Prior TNF-α Inhibitors 